Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Applovin
APP
|
$1.3B |
| 2 |
e.l.f. Beauty
ELF
|
$339M |
| 3 |
DraftKings
DKNG
|
$247M |
| 4 |
Datadog
DDOG
|
$212M |
| 5 |
Pinduoduo
PDD
|
$188M |
Top Sells
| 1 |
Tesla
TSLA
|
$2.11B |
| 2 |
NVIDIA
NVDA
|
$1.42B |
| 3 |
Spotify
SPOT
|
$1.08B |
| 4 |
Mercado Libre
MELI
|
$668M |
| 5 |
Moody's
MCO
|
$588M |
Sector Composition
| 1 | Consumer Discretionary | 30.95% |
| 2 | Technology | 29.07% |
| 3 | Communication Services | 17.02% |
| 4 | Healthcare | 9.5% |
| 5 | Financials | 5.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Calix
CALX
$3.88B
| $464K | ﹤0.01% |
13,308
-1,457
| -10% | -$50.8K |
|
252
Bandwidth Inc
BAND
$452M
| $460K | ﹤0.01% |
27,017
-2,966
| -10% | -$50.5K |
|
253
Rexford Industrial Realty
REXR
$9.53B
| $357K | ﹤0.01% |
9,245
-236,431
| -96% | -$9.14M |
|
254
Healthcare Realty
HR
$6.11B
| $333K | ﹤0.01% |
19,628
-18,814
| -49% | -$319K |
|
255
Expensify
EXFY
$182M
| $249K | ﹤0.01% |
74,307
-855,978
| -92% | -$2.87M |
|
256
Cardlytics
CDLX
$54.3M
| $187K | ﹤0.01% |
50,413
-516,983
| -91% | -$1.92M |
|
257
Spire Global
SPIR
$284M
| $187K | ﹤0.01% |
13,259
| – | – |
|
258
Sutro Biopharma
STRO
$80.6M
| $89.8K | ﹤0.01% |
48,791
-1,470,550
| -97% | -$2.71M |
|
|
NCNA
259
NuCana
NCNA
$5.69M
| $43.7K | ﹤0.01% |
36,704
| – | – |
|
260
Teradyne
TER
$19.2B
| $39.3K | ﹤0.01% |
312
+22
| +8% | +$2.77K |
|
261
CRH
CRH
$74.7B
| $35.1K | ﹤0.01% |
379
-12
| -3% | -$1.11K |
|
262
Stantec
STN
$12.4B
| $30.5K | ﹤0.01% |
389
+89
| +30% | +$6.98K |
|
263
Veeva Systems
VEEV
$44.1B
| $23.1K | ﹤0.01% |
110
-15,239
| -99% | -$3.2M |
|
264
Unilever
UL
$156B
| $22.6K | ﹤0.01% |
398
+87
| +28% | +$4.93K |
|
265
Rio Tinto
RIO
$101B
| $18.8K | ﹤0.01% |
319
+37
| +13% | +$2.18K |
|
266
AB InBev
BUD
$120B
| $5.01K | ﹤0.01% |
100
| – | – |
|
267
Novo Nordisk
NVO
$251B
| $4.56K | ﹤0.01% |
53
| – | – |
|
268
TotalEnergies
TTE
$137B
| $3.16K | ﹤0.01% |
+58
| New | +$3.16K |
|
269
Li Auto
LI
$24.7B
| $2.69K | ﹤0.01% |
112
+72
| +180% | +$1.73K |
|
270
Genmab
GMAB
$15.9B
| $1.13K | ﹤0.01% |
54
| – | – |
|
271
Scilex Holding
SCLX
$130M
| $223 | ﹤0.01% |
523
| – | – |
|
272
Alector
ALEC
$262M
| – | – |
-78,835
| Closed | -$367K |
|
273
Ascendis Pharma
ASND
$11.8B
| – | – |
-21,403
| Closed | -$3.2M |
|
274
BCE
BCE
$23.3B
| – | – |
-31,257
| Closed | -$1.09M |
|
275
CRISPR Therapeutics
CRSP
$4.79B
| – | – |
-364,768
| Closed | -$17.1M |
|